SL Science Holding LimitedSLBT
Key ratios
FCF / Sales
8.1%2024
2023
-300.0%
Net margin
-72.5%TTM
2024
-35.4%2023
45.4%
ROA
-14.7%2024
ROE
-25.6%2024
Revenue growth
282.7%TTM
2024
282.7%
Recent news
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma
Track SLBT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer